Enliven Therapeutics CFO Hohl sells $231,545 in shares

Benjamin Hohl, Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), sold 6,018 shares of the company’s common stock on October 19, 2026, for a total value of approximately $231,545. These sales followed the exercise of options to acquire an equal number of shares. Both transactions were conducted under a Rule 10b5-1 trading plan adopted by Mr. Hohl on March 18, 2026.

The shares were sold at a weighted average price of $38.4755 per share, with individual sale prices ranging from $37.785 to $38.765. The stock has since risen to $41.82, reflecting a remarkable year for shareholders with a 97% return over the past twelve months. Despite this strong performance, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value, placing it among companies on the most overvalued list. Investors can access 5 additional InvestingPro Tips for deeper insights into ELVN’s valuation and prospects.

Earlier on the same day, Mr. Hohl acquired 6,018 shares of common stock by exercising stock options at a price of $14.85 per share, totaling $89,367. The option, originally for 185,000 shares, vested as to one-fourth of the shares on February 13, 2025, with the remainder vesting in 36 equal monthly installments thereafter.

Following these reported transactions, Mr. Hohl directly holds 38,000 shares of Enliven Therapeutics common stock. He also beneficially owns 175,000 derivative securities in the form of stock options. Certain of these securities are restricted stock units (RSUs), which represent a contingent right to receive one share of the company’s common stock, subject to applicable vesting schedules and conditions.

In other recent news, Enliven Therapeutics has seen significant developments regarding its upcoming clinical trials and analyst ratings. The company announced alignment with the FDA on the design of its planned Phase 3 ENABLE-2 trial, which will evaluate relcobatinib (ELVN-001) in second-line or later chronic myeloid leukemia patients. This trial is set to enroll approximately 450 patients and is expected to start by the end of 2026. Following this announcement, Guggenheim reiterated a Buy rating with a $78.00 price target, while H.C. Wainwright raised its price target to $73 from $65, maintaining a Buy rating.

Additionally, Morgan Stanley initiated coverage on Enliven Therapeutics with an overweight rating and a $70.00 price target. JPMorgan also initiated coverage with an Overweight rating and a $75.00 price target, highlighting ELVN-001 as a differentiated chronic-phase CML asset. William Blair initiated coverage with an outperform rating, noting the expanding chronic myeloid leukemia market and the need for treatment options with improved benefit-risk balance. These recent developments reflect growing interest and optimism among analysts regarding Enliven Therapeutics’ potential in the oncology field.